Reversal of diabetes-induced rat graft transplant coronary artery disease by metformin

Systemic Inflammation and Metabolic Syndrome in Cardiac Allograft Vasculopathy

“…Enhanced efforts to control the metabolic syndrome in heart transplant recipients appear warranted; animal transplant models suggest the possibility of favorable effects on CAV. 36 Given the fact that, in our study, the freedom from CAV at 5 years after study entry and 10 years after transplantation was 65% in patients with TG/HDL Ͻ3 and CRP Ͻ3 mg/liter, one may consider less rigid use of surveillance angiography in these patients.…”

Graft coronary artery disease in murine cardiac allografts: Proposal to meet the need for standardized assessment

“…Many animal models have been described that report the histologic findings of GCAD. [5][6][7][8] One of the advantages of mouse models is the accelerated life cycle of mice, which allows investigation of a chronic disease such as GCAD in a considerably shortened period of time. Another important feature is that transgenic mouse strains may be used to study the effects of different genes on GCAD pathogenesis.…”

Cardiac Allograft Vasculopathy and Insulin Resistance—Hope for New Therapeutic Targets

“…78 Nevertheless, we believe that a more aggressive approach directed at close monitoring and treatment of the metabolic abnormalities associated with insulin resistance syndrome is necessary to prevent CAV and improve longterm prognosis. In addition, specific therapies such as thiazolidinediones (TZD) compounds and metformin, shown to be effective in correcting insulin resistance (IR) and improving cardiovascular prognosis in the general population, 79 and in experimental models, 28,42 offer new and promising therapeutic targets for CAV prevention that warrant testing in randomized controlled trials. If well designed, such trials will undoubtedly further our understanding of the pathophysiology of CAV.…”